GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Oct. 17—I've seen a trend lately called "10 before the end." It's two-faceted. A reader gives 10 recommendations to read by the end of the year and then provides the 10 books they want to finish ...

(Bloomberg) -- Eldridge Industries has agreed to buy 10% of a Blue Owl Capital Inc. fund that owns minority stakes in top-tier alternative asset managers including Vista Equity Partners and Silver ...

Investors often hold blue-chip stocks at the core of their portfolios ... We think Pfizer stock is worth $42 per share. Roche stock trades 29% below our fair value estimate of $55 per share.

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That's because these ...

Commissions do not affect our editors' opinions or evaluations. Blue chip stocks are the cornerstone of buy-and-hold portfolios. Although there is no formal definition for a blue chip stock ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

MACHESENEY PARK, Ill. (WTVO/WQRF) — For the second time in Belvidere North’s history, the football program has finished the regular season on top of the NIC-10. The Blue Thunder are sharing ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled. The withdrawal, which ApexOnco reported earlier ...